Cardiff Oncology, Inc. CRDF
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Cardiff Oncology, Inc. (CRDF) is a healthcare company listed in the US with a market value of about $56M. In the twelve months to September 30, 2026 it had revenue of $559000 and net income of -$38M, a net margin of -6735.2%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 10% a year, a 5-year average ROIC of -52%.
About Cardiff Oncology
Cardiff Oncology is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $280178 in 2014 to $593000 in 2025, growth of about 7.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 53% over three years (dilution for shareholders). It spends 5958% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $559000 | $593000 | $683000 | $488000 | $386000 | $359000 | $365993 | $244632 | $378325 | $505404 | $381072 |
| Net income | -$38M | -$46M | -$45M | -$41M | -$39M | -$28M | -$19M | -$16M | -$16M | -$25M | -$39M |
| Free cash flow | -$40M | -$38M | -$38M | -$31M | -$35M | -$23M | -$17M | -$13M | -$13M | -$23M | -$32M |
| EPS (diluted) | $-0.55 | $-0.69 | $-0.95 | $-0.93 | $-0.89 | $-0.73 | $-1.08 | $-2.80 | $-8.26 | $-51.76 | $-98.64 |
| Net margin | -6735.2% | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7880.5% | -5275.2% | -6709.7% | -4351.1% | -4928.1% | -10287.8% |
| ROIC | — | -105.9% | -57.6% | -49.9% | -28.9% | -15.9% | -11.7% | -145.8% | -133.6% | -258.0% | -87.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $6.28, 765% above the current price; targets range from $1.20 to $12.00; the consensus rating is “Buy”; expected EPS is $-0.56 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Cardiff Oncology pay a dividend?
Not currently.
Is Cardiff Oncology a good stock to buy?
We do not give buy or sell advice. Cardiff Oncology scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.